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Abstract. Long-circulating liposomes, such as PEG-liposomes, are frequently studied for drug delivery
and diagnostic purposes. In our group, poly(amino acid) (PAA)-based coatings for long-circulating
liposomes have been developed. These coatings provide liposomes with similar circulation times as
compared to PEG-liposomes, but have the advantage of being enzymatically degradable. For PEG-
liposomes it has been reported that circulation times are relatively independent of their physicochemical
characteristics. In this study, the inﬂuence of factors such as PAA grafting density, cholesterol inclusion,
surface charge, particle size, and lipid dose on the circulation kinetics of PAA-liposomes was evaluated
after intravenous administration in rats. Prolonged circulation kinetics of PAA-liposomes can be
maintained upon variation of liposome characteristics and the lipid dose given. However, the use of
relatively high amounts of strongly charge-inducing lipids and a too large mean size is to be avoided. In
conclusion, PAA-liposomes represent a versatile drug carrier system for a wide variety of applications.
KEY WORDS: biodistribution; liposome clearance; long-circulating liposomes; pharmacokinetics;
poly(amino acid)s.
INTRODUCTION
Liposomes have repeatedly shown to be able to improve
the therapeutic index of a variety of drugs. Intravenously
administered liposomes generally undergo extensive opsoni-
zation and are therefore rapidly cleared by macrophages of
the mononuclear phagocyte system (MPS), particularly
Kupffer cells in the liver and spleen macrophages. As a
result, liposome targeting to pathological tissues is impeded.
This drawback could be amended by coating liposomes with
hydrophilic, neutral polymers such as polyethylene glycol
(PEG) (1). PEG increases the hydrophilicity of the liposome
surface and provides a steric barrier against opsonization (1,
2). The resulting long-circulating liposomes, also referred to
as Fstealth_ or Fsterically stabilized_ liposomes, are still
removed from the blood circulation, however, removal
occurs at a much lower rate and with less involvement of
the hepatosplenic macrophages. Consequently, they circulate
in the bloodstream for a prolonged period of time, enabling
their extravasation into solid tumors and sites of inﬂamma-
tion by virtue of the presence of capillary discontinuities.
This so-called enhanced permeability and retention (EPR)
effect allows for increased local drug concentrations in the
target region (3).
Besides PEG, several other hydrophilic polymers have
been successfully applied as coatings for long-circulating
liposomes, among them conjugates based on poly(oxazoline)
(4), polyglycerol (5), poly(N-(2-hydroxypropyl)methacryl-
amide)) (6), poly-N-vinylpyrrolidone (7, 8) and polyvinyl
alcohol (9). Our group proposed liposome coatings based on
poly(amino acid)s (PAA): poly(hydroxyethyl L-glutamine)-N-
succinyldioctadecylamine (PHEG-DODASuc) and poly
(hydroxyl-ethyl L-asparagine)-DODASuc (PHEA-DODA-
Suc) (Fig. 1)( 10, 11). PAAs have the advantage of being
degradable by lysosomal proteases, allowing for a complete
elimination from the body, and reducing the risk of side effects
associated with polymer accumulation, as described to occur in
case of some non-degradable polymers (12–15). Their degrad-
ability can also be exploited for enzyme-induced drug release
and/or target cell interaction, as the coating may be shed by
proteolytic cleavage in the extracellular space of tumors and
sites of inﬂammation. It has been demonstrated that PAA
coatings can prolong circulation times of liposomes to an equal
extent as a PEG coating (10).
An understanding of the effect of physicochemical
characteristics of long-circulating liposomes on their phar-
macokinetics and biodistribution is crucial for the rational
development of therapeutic applications. Liposome clearance
is a very complex mechanism and is mediated by a diversity
of protein molecules such as immunoglobulins, complement
factors and nonimmune opsonins, and the opsonization
process can be very different for different types of liposomes
(16–18). For long-circulating liposomes with PEG as a
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pharm.uu.nl)Fstealth’ coating, it has been reported that circulation times
are relatively independent of factors such as lipid dose, lipid
composition, surface charge and liposome size, which makes
them versatile drug carriers (19). In the present study, we
investigated if this also holds true for PAA-liposomes.
Therefore, the inﬂuence of PAA grafting density, cholesterol
inclusion, surface charge, particle size and lipid dose on the
circulation kinetics and biodistribution of PAA-liposomes
was evaluated.
MATERIALS AND METHODS
Materials
PHEA-DODASuc (average MW=3,000 Da, determined
by NMR and MALDI-ToF MS, corresponding with an average
degree of polymerization of 15) and PHEG-DODASuc (aver-
age MW=4,000 Da, determined by NMR and MALDI-ToF
MS,corresponding withanaverage degreeofpolymerization of
18) were synthesized as described previously (10). Dipalmitoyl
phosphatidylcholine (DPPC), egg phosphatidylcholine (EPC)
and egg phosphatidylglycerol (EPG) were kindly provided
by Lipoid GmbH, Ludwigshafen, Germany. 1,2-Dioleoyl-3-
trimethylammonium-propane (DOTAP) and L-a-phosphatidyl
serine (PS, porcine brain, sodium salt) were purchased from
Avanti Polar Lipids, Inc., Alabaster, AL, USA. Cholesterol
was purchased from Sigma-Aldrich Chemie BV, Zwijndrecht,
The Netherlands. [
3H]-Cholesteryl oleylether was a product of
Amersham, Roosendaal, The Netherlands. Ultima Gold liquid
scintillation cocktail and Solvable tissue solubilizer were
purchased from Perkin Elmer BioScience B.V., Groningen,
The Netherlands. All other reagents were of analytical grade.
Animals
Male outbred Wistar rats (body weight approximately
250 g) were obtained from Harlan Nederland, Horst, The
Netherlands. Rats were housed in groups of four under
standard laboratory conditions and had free access to rat
chow and water. All animal experiments were performed
according to national regulations and approved by the local
animal experiments ethical committee.
Liposome Preparation
Liposomes were prepared as described previously by a
l i p i dﬁ l mh y d r a t i o nm e t h o d( 20). Appropriate amounts of
DPPC, EPC, EPG, cholesterol, PS, or DOTAP were dissolved
in ethanol in 50 ml round-bottom ﬂasks (for lipid compositions
see Table I). To each formulation 20 mlo ft h el i p i dp h a s e
marker [
3H]-cholesteryl oleylether (approximately 740 kBq)
were added. This label has been shown to be non-
metabolizable and non-exchangeable (21, 22). The solvent
was evaporated under a stream of nitrogen. The obtained lipid
ﬁlm was hydrated by gentle shaking in 2.5 ml HBS (5 mM
HEPES, 0.9% NaCl, pH 7.4) resulting in a ﬁnal concentration
of 20 mmol total lipid/ml, except for two formulations to study
the effect of the lipid dose: besides the formulation of 20 mmol
total lipid/ml, a second formulation was prepared at a
concentration of 0.2 mmol/ml and divided into two equal
parts. One part was diluted 1:10 in HBS, yielding a lipid
concentration of 0.02 mmol total lipid/ml. Liposomes of the
different sizes were obtained by multiple extrusion through
two stacked polycarbonate ﬁlters (Poretics, Livermore, CA,
USA, 400, 200, and 100 nm pore size) with a high-pressure
extruder. Formulations were stored at 4-C and used within 1
week after preparation.
Liposome Characterization
The mean particle size and polydispersity index (PD) of
the liposome dispersions (diluted 1:100 with HBS) were
measured by dynamic light scattering on a Malvern ALV/
CGS-3 Goniometer, detected at an angle of 90- to the laser
beam. The polydispersity index gives information on the
particle size distribution, it ranges from 0 for an entirely
monodisperse up to 1 for a polydisperse system. The
phospholipid content of the liposomal dispersions was
determined colorimetrically according to Rouser et al. (23).
Radioactivity of the liposomal dispersions was analyzed in an
Ultima Gold liquid scintillation cocktail (dilution of 1:1,000)
and counted in a Packard Tricarb 2200 CA liquid scintillation
counter.
Pharmacokinetics
Rats were put under light isoﬂurane anesthesia and
liposomes were injected via the tail vein. To study the
effect of lipid dose, injections of 25, 0.25, and 0.025 mmol
total lipid/kg were given. For all other studies the injected
dose was 20 mmol total lipid/kg. Blood samples (approxi-
mately 150 ml) were drawn under isoﬂurane anesthesia
from the tail vein of each rat immediately after injection
(from the opposite vein) and at 1, 4, 8, 24 and 48 h after
injection. Hundred microliters of each blood sample were
mixed with 100 ml Solvable tissue solubilizer and 100–
200 ml 35% hydrogen peroxide to decolorize the samples
and incubated overnight. Samples were diluted in 10 ml
Ultima Gold scintillation cocktail and radioactivity was
subsequently assessed in a Packard Tricarb 2200CA liquid
scintillation counter. Forty-eight hours after injection, the
rats were sacriﬁced by cervical dislocation and for the
studies involving variations in surface charge, liposome
size and lipid dose, liver and spleen were dissected and
homogenized in 25 and 5 ml water, respectively. To 0.5 ml
of the liver homogenate and 1 ml of the spleen homoge-
nate, 200 ml of Solvable tissue solubilizer and 200 ml3 5 %
hydrogen peroxide were added and mixtures were incu-
bated until samples were dissolved and colorless. Radio-
activity of the samples was assessed in 10 ml Ultima Gold
scintillation cocktail as described above. Besides tissue and
blood samples, also liposome samples were analyzed to
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Fig. 1. Structures of PHEA-DODASuc (average degree of polymer-
ization (n=15) and PHEG-DODASuc (n=18).
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Liposome Characteristic
Studied Liposome Type Formulation Composition (Molar Ratio) Mean size (nm) PD
Size PHEA-liposomes Desired size: 360 nm EPC/EPG/PHEA-
DODASuc 1.425:
1.425:0.15
355 0.26
Desired size: 230 nm EPC/EPG/PHEA-
DODASuc 1.425:
1.425:0.15
230 0.13
Desired size: 120 nm EPC/EPG/PHEA-
DODASuc 1.425:
1.425:0.15
120 0.07
PHEG-liposomes Desired size: 360 nm EPC/EPG/PHEG-
DODASuc
1.425:1.425:0.15
370 0.21
Desired size: 230 nm EPC/EPG/PHEG-
DODASuc 1.425:
1.425:0.15
225 0.13
Desired size: 120 nm EPC/EPG/PHEG-
DODASuc 1.425:
1.425:0.15
125 0.02
Grafting density PHEA-liposomes Grafting density: 2.5% DPPC/cholesterol/
PHEA-DODASuc
1.95:1:0.05
145 0.08
Grafting density: 7.5% DPPC/cholesterol/
PHEA-DODASuc
1.85:1:0.15
145 0.04
Grafting density: 15% DPPC/cholesterol/PHEA-
DODASuc 1.7:1:0.3
135 0.05
Cholesterol content PHEA-liposomes Without cholesterol EPC/PHEA-DOD
ASuc 2.85:0.15
135 0.14
With cholesterol EPC/cholesterol/PHEA-
DODASuc 1.85:1:0.15
140 0.08
PHEG-liposomes Without cholesterol EPC/PHEG-DOD
ASuc 2.85:0.15
150 0.10
With cholesterol EPC/cholesterol/PHEG-
DODASuc 1.85:1:0.15
145 0.06
Negative charge PHEA-liposomes EPC EPC/PHEA-
DODASuc 2.85:0.15
135 0.14
EPC/EPG 4:1 EPC/EPG/PHEA-DODA
Suc 2.25:0.6:0.15
125 0.06
EPC/EPG 1:1 EPC/EPG/PHEA-DODA
Suc 1.425:1.425:0.15
125 0.01
EPC/PS EPC/PS/PHEA-DODA
Suc 2.55:0.3:0.15
105 0.09
PHEG-liposomes EPC EPC/PHEG-
DODASuc 2.85:0.15
150 0.10
EPC/EPG 4:1 EPC/EPG/PHEG-DODA
Suc 2.25:0.6:0.15
160 0.13
EPC/EPG 1:1 EPC/EPG/PHEG-DODA
Suc 1.425:1.425:0.15
135 0.03
EPC/PS EPC/PS/PHEG-DODA
Suc 2.55:0.3:0.15
120 0.05
Positive charge PHEA-liposomes EPC/DOTAP/
PHEA-DODASuc
1.425:1.425:0.15
125 0.05
PHEG-liposomes EPC/DOTAP/PHEG-
DODASuc 1.425:1.
425:0.15
120 0.06
Lipid dose PHEG-liposomes Lipid dose: 25 mmol/kg EPC/EPG/PHEG-DOD
ASuc 1.425:1.425:0.15
135 0.05
Lipid dose: 0.25 and 0.025
mmol/kg
EPC/EPG/PHEG-DODA
Suc 1.425:1.425:0.15
120 0.10
2396 Romberg et al.determine the radioactivity of the injected amount of
liposomes.
Data Analysis
Blood concentrations of liposomes at the different time
points were calculated from the radioactivity of the blood
samples as the percentage of the radioactivity measured
immediately after injection (% injected dose). For the blood
samples, a Q-test for identiﬁcation of outliers was applied.
From the blood concentration-time curves, area under the
curvevalueswerecalculatedfortheanalyzedtimeintervalfrom
zero to 48 hours using the trapezoidal rule [AUC0–48 h (%
injected doseh)]. The percentage of the injected dose (% ID)
in the organs was calculated by division of the radioactivity of
the organs by the radioactivity of the injected liposome
amount. Differences in AUCs and liver and spleen values
were compared by a one-way analysis of variance. The
Bonferroni method was used to correct for multiple compar-
ison. Differences were considered signiﬁcant when the p-value
was <0.05. All analyses were performed using Graph Pad
Prism 4 software.
RESULTS AND DISCUSSION
To study the effect of liposome characteristics on the
pharmacokinetics and biodistribution, different liposome
types were prepared. Liposome compositions, sizes and
polydispersity indices are presented in Table I. Different
grafting densities of PAAs on the liposome surface were
studied. The bilayer ﬂuidity of liposomes was varied by
inclusion of cholesterol. The effect of charge was examined
by inclusion of the negatively charged lipids egg phosphati-
dylglycerol (EPG) and phosphatidylserine (PS) and the
positively charged lipid dioleoyl phosphatidyltrimethylam-
monium propane (DOTAP). The effect of particle size was
assessed with liposomes of sizes between 120 and 360 nm.
The lipid doses needed in therapeutic settings can differ
substantially. PEG-liposomes show dose-independent phar-
macokinetics over a broad dose range, however at low doses
(<1 mmol/kg) rapid clearance has been reported. To investi-
gate if this also holds true for PAA-liposomes, the effect of
lipid dose on the pharmacokinetics of PAA-liposomes was
examined. Except for liposome formulations prepared to
study the effect of liposome size, the hydrodynamic diameter
of liposomes varied between 105 and 160 nm and the
polydispersity index was e0.14, indicating a relatively narrow
size distribution.
Effect of Grafting Density
In Table II the effect of three different grafting levels of
PHEA-DODASuc (i.e. 2.5, 7.5 and 15 mol%) on the
circulation kinetics of liposomes is shown. For this study the
composition of DPPC and cholesterol (2:1) was chosen to be
able to compare the data to earlier published results on the
effect of grafting density of PHEG-DODASuc (1, 2.5, 7.5 and
15 mol%) on liposome circulation times (10). The blood
concentrations at 4 and 24 h post-injection show no
signiﬁcant differences between the formulations. This is in
line with the ﬁndings on the effect of grafting density of
PHEG-DODASuc on liposome circulation times (10). The
density of stealth polymers on the liposome surface has been
shown to be of importance in the design of long-circulating
liposomes. For example, for PEG-liposomes with a PEG2000-
conjugate a grafting density of 5 to 7.5 mol% is often used in
preclinical studies (24, 25). At PEG levels >4 mol%, a
transition from the mushroom state, where PEG chains do
not interact laterally, to the denser and thicker brush state of
PEG occurs, the latter being the condition for optimal steric
stabilization of the liposomes (26). It has been shown that a
further increase of the density of PEG up to 20 mol% did not
change circulation kinetics and biodistribution. However,
considerable foaming made liposome preparation difﬁcult;
the foaming was likely related to the presence of PEG-DSPE
micelles (24). Our studies show that at grafting densities
between 2.5 and 15%, PAAs are able to prolong liposome
circulation times similar to PEG. In previous studies a PAA
grafting density of 7.5% was used, however, the present study
indicates that a lower grafting density of 2.5% is also
sufﬁcient to prolong liposome circulation times.
Table II. Percentage of Injected Dose of PHEA-Coated DPPC/
Cholesterol Liposomes in the Circulation at 4 and 24 h Post-Injection
PHEA-DODASuc Grafting Density (%)
Blood Concentration
(% ID)
4h
a 24 h
b
2.5 50T23 16T11
7.5 55T82 1 T2
15 60T52 0 T2
Results are expressed as meanTSD (n=3–4).
a,bDifferences not signiﬁcant
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Fig. 2. Pharmacokinetic behavior of EPC-liposomes coated with
PHEA (top left) and PHEG (top right) without (empty squares)o r
with (ﬁlled squares) 33% cholesterol (% injected dose). Area under
the curve (AUC0–48 h)v a l u e s( bottom) calculated from blood
concentration time curves. All results are expressed as meanTSD
(n=3–4). *p<0.05; n.s. Not signiﬁcant.
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The circulation kinetics of EPC-based liposomes without
or with 33 mol% cholesterol and coated with PHEA or
PHEG were determined (Fig. 2). For both PHEA- and
PHEG-liposomes, only small differences in circulation pro-
ﬁles and AUC values of liposomes with or without choles-
terol were observed. Cholesterol is known to inﬂuence the
bilayer ﬂuidity, resulting in increased rigidity and lateral
packing and an increased phase transition temperature (27).
For conventional PC-based liposomes interaction with pro-
teins was reduced and circulation times were extended upon
inclusion of cholesterol (28, 29). For PEGylated liposomes
controversial observations have been made. Addition of 20–
50 mol% cholesterol resulted in improved circulation kinetics
(25). In other studies, however, no differences in circulation
times and biodistribution have been observed when 33 mol%
cholesterol were added, indicating that differences in bilayer
rigidity have only little inﬂuence on the circulation kinetics of
liposomes that are shielded by a Fstealth_ coating (30, 31).
Our ﬁndings are in agreement with this observation made
with PEG-liposomes: shielding of liposomes by PAAs
diminished the inﬂuence of bilayer ﬂuidity on circulation
times.
Effect of Charged Lipids
Charged lipids are often added to liposome formulations
to improve drug loading and/or stability of the formulation
against aggregation during storage (30, 31). Changing the
surface charge of conventional liposomes has been shown to
greatly inﬂuence their pharmacokinetic behavior (32, 33). For
PEG-liposomes it has been reported that the polymer is able
to shield liposome charge. For example, PEG-liposomes
containing up to 30 mol% of the negatively charged
phospholipid EPG showed no altered pharmacokinetic
behavior (30, 31). This is in line with our ﬁndings that
inclusion of 20 mol% of EPG in PAA-coated liposomes did
not result in signiﬁcant changes in circulation kinetics and
biodistribution (Fig. 3 and Table III). When 47.5 mol% of
this lipid were included, only a slight decrease in circulation
times was observed.
When the negatively charged phospholipid PS was
included in PHEA- and PHEG-liposomes at a level of
10 mol%, a very rapid removal from the circulation was ob-
served. Apparently, at the grafting density level of 5 mol%,
PAAs are not able to sufﬁciently shield PS-containing
liposomes from opsonization. This is in line with the ﬁndings
that 5 mol% of PEG was not effective in protecting PS-
containing liposomes from rapid clearance (24). PS contain-
ing PAA-liposomes showed an enhanced liver distribution
when compared to PAA-liposomes containing EPG. The
results indicate that PAA-coatings are able to shield the
surface of EPG-containing liposomes more effectively than
that of PS-containing liposomes. It has been suggested that
the position of the negative charge within the molecule might
play a role in the differences in shielding capacity (33). The
negatively charged carboxyl group of PS is located at the
terminal position of the hydrophilic part of the molecule,
directed to the outer ﬂuid, whereas the negatively charged
phosphate group of EPG is located closer to the hydrophobic
anchor and therefore shielded more effectively by the
coating. In addition, the observed differences in pharmaco-
kinetics of both types of liposomes may be related to the
involvement of a receptor recognition mechanism in case of
the PS-containing PAA-liposomes (33). PS has important
physiological functions, it serves as signal for recognition and
removal of aged erythrocytes and apoptotic cells by macro-
phages, which display a PS-speciﬁc receptor (34). In addition,
it binds to clotting factors and initiates coagulation (35, 36).
Fig. 3. Pharmacokinetic behavior of EPC liposomes with a negative
charge. EPC-liposomes (ﬁlled diamonds), EPC/EPG-liposomes in a
molar ratio of 4:1 (ﬁlled circles)o r1 : 1( ﬁlled squares) and EPC/PS-
liposomes (9:1) (ﬁlled triangles) coated with PHEA (top left)a n d
PHEG (top right) (% injected dose). Area under the curve (AUC0-48h)
values (bottom) calculated from blood concentration time curves. All
results are expressed as meanTSD (n=3–4). **p<0.01; *p<0.05; n.s. Not
signiﬁcant.
Table III. Percentage of Injected Dose of PHEA- and PHEG-
Coated EPC-Liposomes with or without a Negative Charge in Liver
and Spleen 48 h Post-Injection
Liposomes
Liver
[% ID]
a
Spleen
[% ID]
b
PHEA-liposomes EPC 15T27 T1
EPC/EPG 4:1 10T31 1 T1
EPC/EPG 1:1 8T17 T2
EPC/PS 27T21 2 T1
PHEG-liposomes EPC 19T39 T1
EPC/EPG 4:1 12T31 5 T1
EPC/EPG 1:1 12T17 T3
EPC/PS 19T39 T2
Results are expressed as meanTSD (n=3–4).
ap<0.05 for PHEA/EPC vs PHEA/EPC/EPG 4:1 and vs PHEA/
EPC/EPG 1:1 and vs PHEA/EPC/PS, PHEA/EPC/EPG 4:1 and vs
PHEA/EPC/PS, PHEA/EPC 1:1 vs PHEA/EPC/PS, PHEG/EPC vs
PHEG/EPC/EPG 1:1, PHEG/EPC/PS vs PHEG/EPC/EPG 4:1 and
vs PHEG/EPC/EPG 1:1
bp<0.05 for PHEA/EPC vs PHEA/EPC/EPG 4:1 and vs PHEA/
EPC/PS, PHEA/EPC/EPG 1:1 vs PHEA/EPC/EPG 4:1 and vs
PHEA/EPC/PS, PHEG/EPC/EPG 4:1 vs PHEG/EPC and vs
PHEG/EPC/EPG 1:1 and vs PHEG/EPC/PS
2398 Romberg et al.PS-containing liposomes are known to bind high amounts of
plasma proteins. They are rapidly cleared from the circula-
tion by the MPS, show in particular high uptake by Kupffer
cells of the liver and activate the complement system (37, 38).
The differences in pharmacokinetics between the differ-
ently charged formulations were not reﬂected in the distri-
bution to liver and spleen. However, it should be realized
that the presented data likely give an underestimated
impression of the actual hepatosplenic accumulation, as at
48 h post-injection liposomes may have already been subject
to substantial degradation and consequently redistribution of
the label may have occurred.
Besides liposomes with a negative surface charge, PAA-
coated liposomes prepared with 47.5 mol% of the positively
charged lipid DOTAP were studied. These cationic lipo-
somes were very rapidly cleared from the bloodstream, in-
dependent of the type of PAA-coating. Less than 1% of the
administered dose was detected in the blood circulation one
hour after injection of PHEA- or PHEG-liposomes. Cationic
liposomes have been reported to interact strongly with blood
components and may even induce aggregate formation in the
circulation (29, 39, 40). PHEA and PHEG at a grafting
density of 5 mol% are apparently not capable to shield and
prolong the circulation times of cationic liposomes containing
high levels of DOTAP (47.5 mol%).
Effect of Particle Size
The circulation kinetics and AUC values of PHEA- and
PHEG-liposomes of approximately 360, 230 and 120 nm are
shown in Fig. 4. Table IV summarizes their distribution to
liver and spleen. Liposomes with a mean size of 120 nm were
removed from the bloodstream at a lower rate than lipo-
somes of 230 and 360 nm, respectively, for both PHEA- and
PHEG-coated liposomes. This observation has also been
reported in independent studies for conventional and PEGy-
lated liposomes (25, 30, 32, 41–43). PEG-liposomes with a
diameter of more than 200 nm are more rapidly cleared than
liposomes with a diameter between 100 and 200 nm. A
decrease in size has been shown to also reduce recognition by
the complement system (44–46). At 48 hours after adminis-
tration, the liposome formulation tested showed only small
differences regarding the degree of uptake by liver and
spleen. As mentioned above, differences may have been
obscured as at this late time point redistribution of the label
may already have occurred. Our results indicate that, as
observed for PEG-liposomes, also for PHEA- and PHEG-
liposomes a particle size below 150 nm is the most optimal to
achieve long-circulation properties.
Fig. 4. Pharmacokinetic behavior of EPC/EPG (1:1) liposomes
coated with PHEA (top left) and PHEG (top right) of 360 nm (ﬁlled
squares) 230 nm (ﬁlled circles) and 120 nm (ﬁlled diamonds)( %
injected dose). Area under the curve (AUC0–48 h) values (bottom)
calculated from blood concentration time curves. All results are
expressed as meanTSD (n=4). **p<0.01; n.s. Not signiﬁcant.
Table IV. Percentage of Injected Dose of PHEA- and PHEG-
Coated EPC/EPG Liposomes in Liver and Spleen 48 h Post-Injection
Liposomes Size (nm) Liver (% ID)
a
Spleen
(% ID)
b
PHEA-liposomes 350 16T32 6 T2
230 14T42 6 T7
120 10T31 6 T2
PHEG-liposomes 350 22T81 5 T2
230 18T42 3 T6
120 11T31 8 T3
Results are expressed as meanTSD (n=4).
ap<0.05 for PHEG-liposomes 350 nm vs PHEG-liposomes 120 nm
bp<0.05 for PHEA-liposomes 120 nm vs PHEA-liposomes 230 nm
and vs PHEA-liposomes 350 nm
Fig. 5. Pharmacokinetic behavior of EPC/EPG-liposomes coated
with PHEG at 25 mmol/kg (ﬁlled squares), 0.25 mmol/kg and (ﬁlled
diamonds) 0.025 mmol/kg (ﬁlled squares) (% injected dose) (left).
Area under the curve (AUC0–48 h) values (right) calculated from
blood concentration time curves. All results are expressed as
meanTSD (n=4). n.s. Not signiﬁcant.
Table V. Percentage of Injected Dose of PHEG-Coated EPC/EPG
Liposomes in Liver and Spleen 48 h Post-Injection
Liver [% ID]
a Spleen [% ID]
b
25 mmol/kg 18T11 8 T2
0.25 mmol/kg 19T45 T1
0.025 mmol/kg 22T26 T1
Results are expressed as meanTSD (n=4).
aDifferences not signiﬁcant
bp<0.01 for 25 vs 0.25 mmol/kg and for 25 vs 0.025 mmol/kg
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The effect of the administered lipid dose of PHEG-
liposomes on the circulation kinetics and AUC values is
shown in Fig. 5. No differences in clearance were observed
when liposomes were administered at doses of 25, 0.25, and
0.025 mmol/kg. At 48 hours after administration, liver uptake
was also independent of the lipid dose but spleen uptake was
lower at both lower lipid doses (Table V). For PEG-
liposomes dose-independent kinetics have been observed over
a dose range between 4 and 400 mmol/kg (47). However, at
doses <1 mmol/kg, which are used in case of for instance
diagnostic imaging of tumors and sites of inﬂammation, PEG-
liposomes are much more rapidly cleared from the circulation
(48, 49).
The mechanism behind this Fenhanced clearance effect_ at
low lipid dose is not yet fully understood. It has been suggested
that rapid clearance is mediated by a limited pool of circulating
opsonic factors that interact with PEG-liposomes and induce
phagocytosis. At higher lipid doses, the inﬂuence of this rela-
tively low amount of opsonic factors becomes more restricted
and the majority of the administered liposomes will be long-
circulating (49, 50). For PHEA-liposomes, a recent study
showed dose-independent pharmacokinetics for doses as low
as 0.025 mmol/kg (51). Thepresentstudydemonstratesthat this
is also the case for PHEG-liposomes. This beneﬁt of PAA-
liposomes over PEG-liposomes can be advantageous in sit-
uations in which only low lipid doses of liposomes are required
for the desired application.
CONCLUSION
This study demonstrates that the prolonged circulation
kinetics of PAA-liposomes can be maintained upon variation
of liposome characteristics and the lipid dose given. This
allows the possibility to tailor the liposome composition to
the required properties for achieving efﬁcient drug targeting,
without the risk of negative effects on the long-circulation
property of the PAA-liposomes. However, the use of
relatively high amounts of strongly charge-inducing lipids
and a too large mean size is to be avoided.
In addition to their advantage of being enzymatically
degradable, PAAs are able to sterically stabilize a broad
range of liposomes varying in physicochemical properties and
therefore PAA-liposomes represent a versatile drug carrier
system for a wide variety of applications.
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